ClinicalTrials.gg
CompletedNCT003246883ODUpdated Mar 12, 2014

Safety Study of Once a Day ART and Opiate Substitute.

A Phase 4 interventional study of Viread in HIV Infections, sponsored by Gilead Sciences. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-12.

Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing tenofovir in HIV Infections — 1 open to participants now, 3 under way, 1 of them phase 3. Tenofovir · HIV Infections.

Enrollment
55th of 94
60 · median 99
Started
2003
with 4 others
Phase 4
27 of 98
none open now
Registered
39th of 98
by date
Lead sponsor
17 of 98
Gilead Sciences

Among the 98 studies testing tenofovir in HIV Infections, this one is the 55th largest by enrollment of the 94 interventional ones that give a count, is one of 5 that started in 2003, is one of 27 in phase 4, and was the 39th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 98 studies testing tenofovir in HIV Infections is open now. Recruiting first, the newest first:

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing tenofovir in HIV Infections, or all of them as a file.
02

Study summary

This study looks at HIV-infected subjects who are on methadone treatment and medicines for HIV.

Read the detailed description

Patients with a history of opiate abuse (IVDU) are not only a patient population that is frequently difficult to reach by the healthcare system, but it also exhibits specific problems in HIV-treatment (ART). These patients frequently have a chaotic lifestyle, which makes it difficult to take medications regularly. Amongst the reasons for this are housing difficulties, intoxication and substance abuse.

The introduction of opiate substitution treatment can help to provide some structure and certainty to patients. Even so IVDU patients are often started on ART later than others and have a greater tendency to have treatment interruptions and sub-optimal adherence to ART. The end result can be treatment failure and the development of drug resistance.

There is an unmet medical need for ART regimens that make adherence easier and may be suitable for co-administration with once-daily opiate substitution.

The availability of tenofovir disoproxil fumarate (DF) 300 mg offers new options in the creation of once-daily regimens with reduced potential for drug-drug-interactions. It is believed that it is now possible to construct viable once daily HIV treatment regimens for patients who have either never received prior therapy or who have no history of drug resistance. Tenofovir DF is administered as a single 300 mg tablet once daily with food for the treatment of HIV infection. This once daily dosing schedule of tenofovir DF makes it an attractive option for simplified dosing regimens in many subjects, including methadone-maintained individuals infected with HIV. Because many opiate-maintained subjects are required to have their methadone dosing directly observed in the clinic, there is considerable interest in using directly-observed therapy (DOT) in such subjects. Given that tenofovir is eliminated renally and methadone is predominantly hepatically metabolized, the potential for a pharmacokinetic interaction is low. However, other antiretroviral agents with substantial renal elimination such as didanosine and stavudine have been shown to interact pharmacokinetically with methadone. Thus, it is important to demonstrate that tenofovir DF and methadone can be administered together safely and without concern for a pharmacokinetic interaction and/or alterations in the efficacy, safety, or tolerability of methadone maintenance such that dose modifications would be required. This can also be influenced by the other products in the combination therapy.

HIV/HBV coinfection is a frequent issue in this population (> 20%). Treatment with TDF, which is active against HBV, could help to stabilize the chronic HBV infection, even in cases with Lamivudine-resistance.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV-1
  • Methadone
  • HIV-1 infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18 years or older
  • Previously documented diagnosis of -1 infection:

    • by antibody assay (enzyme immunoassay confirmed by western immunoblot); or
    • positive HIV culture; or
    • detectable plasma HIV-1-RNA levels by reverse transcriptase polymerase chain reaction (RT-PCR).
  • Receiving stable opiate substitution (stable methadone level for ≥ 2 weeks prior to entry into the study) with methadone, levomethadone or buprenorphine
  • Either:

    • Antiretroviral (ARV) therapy-naïve(*) and with:

      • \< 351 cells/µL; and/or
      • HIV-1 plasma levels >= 30,000 copies/mL (*)less than 3 months of ART for vertical transmission is considered as ARV therapy naïve.
    • Or restarting ART after treatment discontinuation with no evidence of prior HIV virological failure (virological failure defined as 2 consecutive measurements 4 weeks apart with viral load of HIV RNA > 400 copies/mL while on ART)
    • Or currently receiving stable ART therapy and with virological suppression (\< 400 copies/mL), for at least 6 months and:

      • suffering from adherence problems because of dosing of current ART; or
      • suffering from side effects on the current recorded ART.
  • Able to give
  • In the opinion of the investigator is likely to be able to complete the study

Exclusion criteria

Exclusion Criteria:

  • Need for antiretroviral therapy which is not according to protocol
  • Pregnant or breastfeeding women
  • Females of not willing to use a barrier method(s) of during heterosexual intercourse during the duration of the study
  • to use of tenofovir DF 300 mg or another concomitant medication
  • Known to the active component or
  • Prior receipt of tenofovir
  • Evidence of clinical, genotypic, or phenotypic resistance to any ARV
  • History of virological failure while on previously recorded ART regimens (virological failure defined as 2 consecutive measurements 4 weeks apart with viral load of RNA > 400 copies/mL)
  • Acute, life-threatening infection or that needs systemic therapy
  • Any clinical laboratory findings obtained during screening that could be a risk factor for the patient during the study:

    • Grade 4 increase of any laboratory value
    • Grade 3 (> 5-10 [ULN] increase in transaminases) at the screening visit
    • Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study requirements.
  • Current use of medication that, in the investigator's opinion or sponsor's opinion, will interfere with the study medication
  • Participation in other clinical trials
  • More than three months of ART treatment for vertical transmission prophylaxis
  • Current receipt of adefovir dipivoxil
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of patients with HIV RNA < 400 and with HIV RNA < 50 copies/mL at Week 48

Secondary outcomes

  1. Proportion of patients with HIV RNA < 400 and with HIV RNA < 50 copies/mL at Week 24

  2. Time to failure or ART discontinuation. Virological failure is defined as 2 consecutive measurements 4 weeks apart with viral load of HIV RNA > 400 copies/mL

  3. Adherence to HIV treatments (Medication Adherence Self-Report Inventory [MASRI] questionnaire, monthly evaluation through patient diary)

  4. Adherence to opiate substitution treatment

  5. Correlation of adherence to ART and HIV RNA levels

  6. Percentage of patients with HIV-1 RNA below limit of detection < 400 copies/mL and 50 copies/mL and adherence level > 95%, > 90%, > 85%, > 80%, > 75%, > 70%, > 50% and < 50%

  7. Dose adjustments for methadone

  8. Proportion of patients with any adverse event (AE)/serious adverse event (SAE)

  9. Proportion of patients with AE/SAE classified by body system

  10. Proportion of patients with each AE/SAE

  11. Distribution of intensity of each AE/SAE (the highest intensity per patient for each event will be considered)

  12. Distribution of relationship to study drug (the strongest relationship to study drug per patient for each event will be considered)

  13. Distribution of toxicity grade (the highest grade per patient for each test will be considered)

07

Study locations

1 site
  • Gilead Sciences
    Munich, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2006
First posted
May 11, 2006
Start
Mar 2003
Completion
Jun 2006
Last update
Mar 12, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Mar 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00324688
Lead sponsor
Gilead Sciences
First posted
May 11, 2006
Start date
Mar 2003
Completion
Jun 2006
Last update
Mar 12, 2014

Study contacts

Thomas Mertenskoetter
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion